These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33672707)

  • 1. Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas.
    Jin M; Song DE; Ahn J; Song E; Lee YM; Sung TY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
    Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not the same thing: metastatic PTCs have a different background than ATCs.
    de Biase D; Torricelli F; Ragazzi M; Donati B; Kuhn E; Visani M; Acquaviva G; Pession A; Tallini G; Piana S; Ciarrocchi A
    Endocr Connect; 2018 Dec; 7(12):1370-1379. PubMed ID: 30400028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
    Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
    Na HY; Yu HW; Kim W; Moon JH; Ahn CH; Choi SI; Kim YK; Choi JY; Park SY
    Clin Endocrinol (Oxf); 2022 Jul; 97(1):106-115. PubMed ID: 35343605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
    Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
    Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
    [No Abstract]   [Full Text] [Related]  

  • 12. MRI features of histological subtypes of thyroid cancer in comparison with CT findings: differentiation between anaplastic, poorly differentiated, and papillary thyroid carcinoma.
    Maeda T; Kato H; Ando T; Kawaguchi M; Shibata H; Ogawa T; Noda Y; Hyodo F; Matsuo M
    Jpn J Radiol; 2024 Sep; ():. PubMed ID: 39289242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
    Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
    Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
    Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling of primary and metastatic thyroid cancers.
    Máximo V; Melo M; Zhu Y; Gazzo A; Sobrinho Simões M; Da Cruz Paula A; Soares P
    Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 38015791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.
    Ghossein RA; Katabi N; Fagin JA
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1414-21. PubMed ID: 23775351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological features and molecular characteristics of tall cell and hobnail variants of papillary thyroid carcinoma].
    Zhang M; Duan HL; Wang LM; Gao W; Yao YY; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1234-1239. PubMed ID: 34719160
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
    Odate T; Oishi N; Kawai M; Tahara I; Mochizuki K; Akaishi J; Ito K; Katoh R; Kondo T
    Endocr Pathol; 2021 Sep; 32(3):347-356. PubMed ID: 33761111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.